Back to top
more

89BIO (ETNB)

(Real Time Quote from BATS)

$9.69 USD

9.69
2,140,327

0.00 (0.00%)

Updated Aug 6, 2025 01:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Tirthankar Chakraborty headshot

4 Best Breakout Stocks to Buy for Superb Returns

by Tirthankar Chakraborty

Coty (COTY), OneSpaWorld (OSW), Mueller Water Products (MWA) and 89BIO (ETNB) have been selected as the breakout stocks for today.

Zacks Equity Research

Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up

by Zacks Equity Research

Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.

Zacks Equity Research

TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down

by Zacks Equity Research

TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.

Zacks Equity Research

Deciphera's (DCPH) Q4 Earnings Miss, Qinlock Drives Revenues

by Zacks Equity Research

Deciphera (DCPH) reports a wider-than-expected loss per share for the fourth quarter of 2022, while revenues driven by Qinlock sales, beat estimates.

Zacks Equity Research

Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod

by Zacks Equity Research

Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult patients.

Zacks Equity Research

Karuna (KRTX) to Obtain Global Rights to Goldfinch's Candidates

by Zacks Equity Research

Karuna Therapeutics (KRTX) announces a definitive agreement with Goldfinch Bio to acquire global rights to the latter's lead clinical-stage candidate, GFB-887 and TRPC4/5 channel candidates.

Zacks Equity Research

Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Blueprint Medicines' (BPMC) sNDA for the label expansion of Aykavit for indolent systemic mastocytosis.

Zacks Equity Research

Biomea (BMEA) Begins Dosing in Lung Cancer Study, Stock Up

by Zacks Equity Research

Biomea Fusion (BMEA) announces the successful dosing of the first patient in phase I/Ib study of BMF-219 in KRAS mutant solid tumors. Stocks rise 11.69% in response.

Zacks Equity Research

89BIO (ETNB) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

89BIO (ETNB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

New Strong Sell Stocks for January 21st

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

Axcella Health (AXLA) Looks Good: Stock Adds 5.9% in Session

by Zacks Equity Research

Axcella Health (AXLA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Equity Research

Why Earnings Season Could Be Great for 89bio (ETNB)

by Zacks Equity Research

89bio (ETNB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Kinjel Shah headshot

5 Biotech Stocks Set to Outpace Q2 Earnings Estimates

by Kinjel Shah

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

Zacks Equity Research

89bio (ETNB) Jumps: Stock Rises 6.9%

by Zacks Equity Research

89bio (ETNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.